loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ipatasertib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ipatasertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche finally dumps phase 3 prostate cancer prospect
    Roche finally dumps phase 3 prostate cancer prospect

    03 Feb 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/akt-over-roche-dumps-phase-3-prostate-cancer-prospect

    Nick Paul Taylor FIERCE BIOTECH
    03 Feb 2023
    Share Share
    Roche scraps 5 trials while Alzheimer's, TIGIT plans still risky
    Roche scraps 5 trials while Alzheimer's, TIGIT plans still risky

    21 Jul 2022

    // James Waldron FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/roche-scraps-5-trials-while-ceo-admits-alzheimers-tigit-ambitions-remain-risky-bets

    James Waldron FIERCEBIOTECH
    21 Jul 2022
    Share Share
    Roche chucks out phase 3 ipatasertib combo tests
    Roche chucks out phase 3 ipatasertib combo tests

    04 Feb 2021

    // Ben Adams FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/roche-chucks-out-phase-3-ipatasertib-combo-tests-midstage-il-33-asthma-btki-arthritis

    Ben Adams FIERCE BIOTECH
    04 Feb 2021
    Share Share
    ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
    ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga

    21 Sep 2020

    // N. P. Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-roche-s-akt-inhibitor-scores-slight-win-over-j-j-s-zytiga

    N. P. Taylor FIERCE BIOTECH
    21 Sep 2020
    Share Share
    SU2C to support clinical trials in breast and prostate cancers
    SU2C to support clinical trials in breast and prostate cancers

    18 Sep 2019

    // CLINEICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/su2c-clinical-trials-teams-launch/

    CLINEICALTRIALSARENA
    18 Sep 2019
    Share Share
    Roche’s ipatasertib combo shows early promise in triple-negative breast cancer
    Roche’s ipatasertib combo shows early promise in triple-negative breast cancer

    03 Apr 2019

    // Anna Smith PHARMA TIMES

    http://www.pharmatimes.com/news/roches_ipatasertib_combo_shows_early_promise_in_triple-negative_breast_cancer_1283208

    Anna Smith PHARMA TIMES
    03 Apr 2019
    Share Share